- Home
- ALGS vs MDBH Comparison
ALGS vs MDBH Comparison
Compare ALGS & MDBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALGS | MDBH |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 29.0M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ALGS | MDBH |
|---|---|---|
| Price | $5.51 | $2.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $39.33 | N/A |
| AVG Volume (30 Days) | ★ 83.9K | 3.8K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,186,000.00 | N/A |
| Revenue This Year | $32.20 | N/A |
| Revenue Next Year | $4.71 | N/A |
| P/E Ratio | ★ N/A | $4.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.80 | $2.45 |
| 52 Week High | $13.69 | $5.50 |
Technical Indicators
Market Signals| Indicator | ALGS | MDBH |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 48.30 |
| Support Level | $4.80 | $2.85 |
| Resistance Level | $6.82 | $3.83 |
| Average True Range (ATR) | 0.36 | 0.20 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 55.34 | 65.06 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
About MDBH MDB Capital Holdings LLC common
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The company operates in two reportable segments: a broker dealer & intellectual property service; and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.